Pulmatrix Inc (PULM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Pulmatrix Inc (PULM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7574
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Pulmatrix Inc (Pulmatrix), formerly Ruthigen Inc is a clinical stage biopharmaceutical company that develops inhaled therapeutic products intended for prevention and treatment of respiratory diseases and infections. The company develops its pipeline product using its proprietary inhaled small particles easily respirable and emitted dry powder delivery technologies. Its pipeline product includes PUR1800, a kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary diseases. Pulmatrix also develops PUR0200, a reformulation of an existing long-acting antimuscarinic agent; and PUR5700, used for the treatment of acute exacerbation of chronic obstructive pulmonary disease, among others. The company also offers clinical trial services. Pulmatrix is headquartered in Lexington, Massachusetts, the US.

Pulmatrix Inc (PULM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Pulmatrix Raises US$6.5 Million In Extended Series B1 Financing 11
Partnerships 12
Capsugel Enters into Agreement with Pulmatrix 12
Pulmatrix Enters Into Alliance with Celdara Medical 13
Pulmatrix Enters into Co-Development Agreement with Mylan 14
Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15
Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Merger 17
Ruthigen Merges with Pulmatrix 17
Licensing Agreements 18
Vectura Group Enters into Licensing Agreement with Pulmatrix 18
Pulmatrix Enters into Licensing Agreement with RespiVert 19
Oculus Innovative Amends the Licensing Agreement With Ruthigen 20
Equity Offering 22
Pulmatrix Prices Public Offering of Units for USD15.2 Million 22
Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24
Pulmatrix Raises USD5 Million in Private Placement of Shares 25
Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26
Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28
Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30
Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For US$20.3 Million 31
Pulmatrix Inc – Key Competitors 33
Pulmatrix Inc – Key Employees 34
Pulmatrix Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
May 11, 2018: Pulmatrix Reports Q1 2018 Results 36
Mar 13, 2018: Pulmatrix Announces 2017 Financial Results 37
Nov 09, 2017: Pulmatrix Provides Q3 2017 Highlights and Q3 2017 Updated Financials 38
Aug 04, 2017: Pulmatrix Provides 2017 Company Year-to-Date Highlights and Q2 2017 Updated Financials 40
May 05, 2017: Pulmatrix Reports Q1 2017 Financial Results 42
Mar 10, 2017: Pulmatrix Reports 2016 Financial Results; Provides 2017 Outlook on Pulmonary Disease Pipeline 43
Corporate Communications 45
Jun 15, 2017: Amit D. Munshi Joins Pulmatrix’s Board of Directors 45
May 03, 2017: Pulmatrix Appoints Ted Raad, MBA, as Chief Business Officer 46
Mar 27, 2017: Pulmatrix Adds Two Top Fungal Infection Experts to its Scientific Advisory Board 47
Product News 48
10/30/2017: Pulmatrix Appoints Dr. James Roach as Chief Medical Officer 48
Product Approvals 49
Oct 03, 2017: Pulmatrix Antifungal Drug Candidate Receives a Second “Qualified Infectious Disease Product” (QIDP) Designation from the FDA 49
Jan 17, 2017: Pulmatrix Drug Candidate Receives “Qualified Infectious Disease Product” Designation from the FDA 50
Clinical Trials 51
Oct 31, 2017: Pulmatrix Presents at the North American Cystic Fibrosis Conference 51
Oct 30, 2017: Pulmatrix Provides Update on its Anti-Inflammatory Drug Candidate PUR1800 52
Sep 05, 2017: Pulmatrix Receives Award from Cystic Fibrosis Foundation Therapeutics to Support Development of PUR1900 for the Treatment of Pulmonary Fungal Infections 53
Other Significant Developments 54
Sep 19, 2017: CEO Robert Clarke Discusses Positive Developments from Partnerships Obtained within the Past Few Months 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Pulmatrix Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Pulmatrix Raises US$6.5 Million In Extended Series B1 Financing 11
Capsugel Enters into Agreement with Pulmatrix 12
Pulmatrix Enters Into Alliance with Celdara Medical 13
Pulmatrix Enters into Co-Development Agreement with Mylan 14
Quotient Clinical Enters Into Agreement With Pulmatrix For PUR0200 15
Pulmatrix Enters Into Co-Development Agreement With Cystic Fibrosis Foundation Therapeutics 16
Ruthigen Merges with Pulmatrix 17
Vectura Group Enters into Licensing Agreement with Pulmatrix 18
Pulmatrix Enters into Licensing Agreement with RespiVert 19
Oculus Innovative Amends the Licensing Agreement With Ruthigen 20
Pulmatrix Prices Public Offering of Units for USD15.2 Million 22
Pulmatrix Raises USD3.3 Million in Private Placement of Shares 24
Pulmatrix Raises USD5 Million in Private Placement of Shares 25
Pulmatrix Raises USD10 Million in Private Placement of Shares and Warrants 26
Pulmatrix Raises USD0.6 Million in Private Placement of Shares 28
Pulmatrix Raises USD0.9 Million in Private Placement of Shares 29
Oculus Innovative Sciences to Sell Remaining Shares of Ruthigen for USD4.5 Million 30
Ruthigen Completes Underwriters Exercise Of Partial Over-Allotment Option Of IPO For US$20.3 Million 31
Pulmatrix Inc, Key Competitors 33
Pulmatrix Inc, Key Employees 34
Pulmatrix Inc, Subsidiaries 35

List of Figures
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pulmatrix Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Pulmatrix Inc (PULM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Omega Diagnostics Group Plc (ODX):企業の財務・戦略的SWOT分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company provides products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests …
  • Santen Pharmaceutical Co Ltd (4536):製薬・医療:M&Aディール及び事業提携情報
    Summary Santen Pharmaceutical Co Ltd (Santen) focuses on the research, development, manufacture and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for bacterial conjunctivitis, glaucoma, dry eye, Inflammation and others; OTC …
  • Isovolta AG:企業の戦略的SWOT分析
    Isovolta AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Energy World Corp Ltd (EWC):電力:M&Aディール及び事業提携情報
    Summary Energy World Corp Ltd (Energy World) is an energy company that produces and sells power and develops liquiefied natural gas projects. The company's activities include design, construction, operation, and maintenance of independent power projects, liquefied natural gas plants, and gas process …
  • General Electric Co (GE)-エネルギー分野:企業M&A・提携分析
    Summary General Electric Company (GE) is a digital industrial company. It offers a range of industrial, infrastructure and financial services globally. The company offers a range of products and services from aircraft engines, power generation and oil and gas production equipment to medical imaging, …
  • Sinclair Oil Corp:企業の戦略的SWOT分析
    Sinclair Oil Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • ACHEM Technology Corporation:企業の戦略・SWOT・財務情報
    ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Secret Recipe Cakes & Cafe Sdn. Bhd.:企業の戦略・SWOT・財務分析
    Secret Recipe Cakes & Cafe Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report Summary Secret Recipe Cakes & Cafe Sdn. Bhd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Packaging Corporation of America:企業の戦略・SWOT・財務分析
    Packaging Corporation of America - Strategy, SWOT and Corporate Finance Report Summary Packaging Corporation of America - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • ContraVir Pharmaceuticals Inc (CTRV):製薬・医療:M&Aディール及び事業提携情報
    Summary ContraVir Pharmaceuticals Inc (ContraVir) is a biopharmaceutical company that offers development and commercialization of targeted antiviral therapies. The company provides pipeline product such as TXL, potent prodrug of antiviral tenofovir and CRV431 cyclophilin inhibitor that increases its …
  • Isagen SA ESP:発電所・企業SWOT分析
    Isagen SA ESP - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • Neiman Marcus Group LTD LLC:企業の戦略的SWOT分析
    Neiman Marcus Group LTD LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • C. Uyemura & Co Ltd (4966):企業の財務・戦略的SWOT分析
    C. Uyemura & Co Ltd (4966) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Viavi Solutions Inc
    Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary Viavi Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Santos Limited:企業のM&A・事業提携・投資動向
    Santos Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Santos Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • H & M Hennes & Mauritz AB:企業の戦略・SWOT・財務情報
    H & M Hennes & Mauritz AB - Strategy, SWOT and Corporate Finance Report Summary H & M Hennes & Mauritz AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • The Warehouse Group Ltd (WHS):企業の財務・戦略的SWOT分析
    The Warehouse Group Ltd (WHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Recro Pharma Inc (REPH):企業の財務・戦略的SWOT分析
    Recro Pharma Inc (REPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Fuji Oil Co Ltd (5017):企業の財務・戦略的SWOT分析
    Fuji Oil Co Ltd (5017) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Ultradent Products Inc:企業の戦略的SWOT分析
    Ultradent Products Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆